Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Medtronic
Baxter
Harvard Business School
Farmers Insurance
Colorcon

Generated: August 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,163,684

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,163,684
Title:Method of increasing bone toughness and stiffness and reducing fractures
Abstract: The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA), Hock; Janet M. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/098,894
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,163,684
Patent Claims:1. A method for treating osteoporosis in a post-menopausal woman at high risk for fracture, comprising administering to said woman human parathyroid hormone (1 34), in a daily dose of 20 ug, without concurrent administration of an antiresorptive agent other than supplemental vitamin D or supplemental calcium, said treatment for increasing bone mineral density and reducing the risk of vertebral and non-vertebral bone fracture.

2. The method of claim 1 wherein said woman has at least one prior fragility fracture.

3. The method of claim 1 wherein the osteoporosis is selected from advanced-stage osteoporosis, hypogonadal osteoporosis, spinal osteoporosis, and steroid-induced osteoporosis.

4. The method of claim 3 wherein the osteoporosis is advanced-stage osteoporosis.

5. The method of claim 3 wherein the osteoporosis is spinal osteoporosis.

6. The method of claim 3 wherein the osteoporosis is steroid-induced osteoporosis.

7. The method of claim 1 wherein concurrent administration of supplemental vitamin D and supplemental calcium is excluded.

8. The method of claim 1 wherein supplemental vitamin D is concurrently administered.

9. The method of claim 1 wherein supplemental calcium is concurrently administered.

10. The method of claim 1 wherein supplemental vitamin D and supplemental calcium are concurrently administered.

Details for Patent 7,163,684

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2018-08-19 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2018-08-19 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2018-08-19 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2018-08-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Johnson and Johnson
AstraZeneca
Daiichi Sankyo
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.